We studied total plasma homocysteine levels (tHcy) in Algerian patients with a deep venous thrombosis (DVT). We measured tHcy levels in a total of 99 subjects enrolled in this study, including 40 patients with DVT and 59 healthy controls. The mean tHcy level in the patients was 12.62 ± 8.7 μmol/L and that in the controls was 10.2 ± 2.1 μmol/L. In a univariate regression model, tHcy concentrations were inversely correlated with triglycerides (TG) (r = -0.358; p = 0.023) and total cholesterol (TC) (r = -0.454; p = 0.003) concentrations. Logistic regression analysis showed that tHcy after adjustment was significantly associated with the following factors: TC (p = 0.003) and TG (p = 0.023). The analysis in DVT patients showed that variables independently associated with tHcy were TC [odds ratio (OR) 2.1, 95% confidence interval (CI) 1.7-2.6], lowdensity lipoprotein cholesterol (OR 2.0, 95% CI 1.6-2.5), creatinine (OR 2.2, 95% CI 1.7-2.6), and smoking (OR 2.1, 95% CI 1.7-2.5). In conclusion, these results indicate that tHcy levels and other biochemical parameters are important determinant factors for DVT diseases in Algerian patients.
Introduction
The increase in the death rate from cardiovascular diseases (CVD) in third world countries may be due to a gradual increased exposure to Westernised lifestyles. Homocysteine (Hcy) is a sulphur-containing amino acid derived from methionine metabolism as an intermediate metabolite.
Since the initial hypothesis by McCully [1] 45 years ago, the relationship between elevated Hcy levels and vascular disease has been confirmed. It is clear that hyperhomocysteinaemia (HHcy) is an independent risk factor for coronary artery disease [2] and venous thrombosis (VT) [3] .
Clinically, the normal concentration of total plasma Hcy (tHcy) ranges between 5 and 15 μmol/L. In recent years, moderate HHcy has been implicated in systematic hypertension, stroke, and other vascular diseases [4] . A high blood pressure, an unfavourable lipid profile (e.g., high total cholesterol level, high low-density lipoprotein and high-density lipoprotein cholesterol levels, and high triglyceride levels), and history of smoking explain the majority of all CVD cases. However, the search for other risk factors remains because not all CVD cases can be explained by these established risk factors. One factor that has been associated with CVD is elevated plasma Hcy concentration [5, 6] .
Venous thromboembolism is the third most prevalent cardiovascular disorder after ischaemic heart disease and stroke, and 1 in 1000 individuals is affected by it annually [7] . The pathogenesis of thrombotic disease is complex and multifactorial, caused by congenital and acquired risk factors. Acquired risk factors include dyslipidaemia, tabagism, hypertension, diabetes mellitus, obesity, and HHcy. The connection between Hcy and thrombosis was identified when it was reported that people with a rare condition called homocystinuria accumulated Hcy in the blood and excreted it in the urine [8] . In addition, thrombotic disease is responsible for 50% of the vascular events in patients with cystathionine β-synthase deficiency [9] . Several studies have been performed since 1991 to investigate the association between Hcy and VT disease. Mild HHcy has been identified as a risk factor for thrombosis both in the arterial and in the venous sites [10] . The epidemiological evidence of Hcy as a risk factor for VT, however, is not as abundant as for arterial thrombotic disease [11] . More case-control studies were subsequently published that confirmed the association between HHcy and VT [12, 13] . Thus, a large number of studies that have analysed the association between HHcy and VT have shown an increased tHcy concentration in patients with DVT [14, 15] .
The prevalence of HHcy in cases of DVT has been extensively studied in the Western population, but there are no studies showing its prevalence in the Algerian population. Whether moderate increases in serum Hcy cause DVT has been the subject of debate. Thus, the present study was undertaken with the aim to investigate tHcy levels in cases of DVT at the Sétif University Hospital (Sétif, Algeria).
Materials and methods

Study participants
This hospital-based, case-control study included 40 DVT patients (17 men and 23 women; gender ratio: 1:1.35), aged 23-85 years (54.0 ± 20.5 years), who were hospitalised at the Cardiology Service of Sétif University Hospital. These patients were enrolled in the Cardiovascular Prevention Program from January to May 2013. All patients with DVT confirmed by Doppler ultrasound were included in the study. In addition, we recruited 59 control subjects (29 men and 30 women; gender ratio: 1:1), aged 42-65 years (48.5 ± 5.8 years), consisting of friends, partners, and employees of the Sétif University Hospital. The control group consisted of asymptomatic subjects aged > 40 years without any history of cardiovascular disease and renal complications. Details of the patients such as name, age, sex, history of smoking, diabetes mellitus, ischaemic heart disease, and hypertension were recorded in the pro forma. All subjects resided in Sétif or in the surrounding areas. Written informed consent was obtained from all the patients, and the study was approved by the Local Ethics Committee of Sétif University Hospital.
Blood sample pre-treatment
Blood samples were collected from controls and patients admitted to Sétif University Hospital after an overnight fast. Venous blood was obtained by puncture of the median cubital vein, collected in EDTA tubes and immediately put on ice, and centrifuged within 1 h at 3000 rpm for 10 min at 4°C. The plasma fraction was aliquoted and stored at -20°C to await analysis of tHcy and other biochemicals.
Biochemical analysis
The concentration of tHcy was determined using a competitive immunoassay on the IMMULITE and IMMULITE 1000 analysers (Siemens Medical Solutions Diagnostics, Los Angeles, CA, USA) using reagents and calibrators. Assays were conducted according to the manufacturer's instruction using the IMMULITE 1000 analyser. Total cholesterol (TC), triglyceride (TG), and creatinine concentrations were measured using the colorimetric method 2 h following the sampling (Synchron CX9 autoanalyser with Beckman Kits, Beckman, USA). HDL cholesterol (HDL-C) and LDL cholesterol (LDL-C) levels were measured using the colorimetric method (COBAS INTEGRA 400, COBAS, Mannheim, Germany). Assays were conducted according to the manufacturer's instructions.
Statistical analyses
All analyses were performed with SPSS version 18.0 for Windows (SPSS Inc., Chicago, IL, USA). The mean and SD values of tHcy and other biochemical parameters were calculated. Statistical analysis for the significance of difference between age, sex, and presence or absence of the risk factors was done using the χ 2 -test. We compared the risk factors between case and control subjects using analysis of variance. The relationship between tHcy, age, TC, LDL-C, HDL-C, TG, and creatinine was calculated by Spearman rank coefficients, and the risk was estimated by a logistic regression model. The adjusted odds ratio (OR) was calculated as an estimate of the relative risk of DVT for individuals with HHcy and other parameters. Multivariate logistic regression analysis was used to estimate the association between Hcy levels and DVT, independently of major risk factors. Differences were considered significant when p < 0.05.
Results
The ratio of female to male subjects among the case patients was 1.35:1 and among the controls was 1:1, and the mean age was 54 years (range 23-85 years) for the case patients and 48.5 years (range 42-65 years) for the controls.
The characteristics of the patients and control subjects as well as the plasma Hcy, TC, LDL-C, HDL-C, and TG levels are shown in Table 1 . Fasting HHcy was considered as the mean of the plasma tHcy for controls ± 2 SD (10.2 ± 2 × 2.1; 14.4 μmol/L in total group). Lower tHcy levels were found for DVT patients (12.62 μmol/L; range 2-50 μmol/L), which did not differ significantly from the values obtained for the control group (10.2 μmol/L; range 6.8-15.5 μmol/L).
A total of 40 patients satisfied the selection criteria. Of these 40 patients, 11 patients were found to have raised serum Hcy levels. The prevalence of HHcy in this study was calculated as 27.5%. We confirmed that total plasma Hcy and creatinine concentrations were higher in DVT patients than in the control subjects (p < 0.05). Our results indicated that total plasma Hcy level and homocysteine/ creatinine ratio were higher in DVT patients than in control subjects (p < 0.05). For subjects with Hcy ≥ 15 μmol/L and creatinine levels > 110 μmol/L, our results indicated that the homocysteine/creatinine ratio was 1.4. Based on analysis with the χ 2 -test, the p-value for the difference in age distribution between the two groups ( ≤ 60 and > 60 years, respectively) was 0.06, showing its insignificance. The prevalence of HHcy among males was 54.6% and that among females was 45.4%. The p-value for the sex distribution difference between the two groups showed that the difference was insignificant.
TC and creatinine levels were higher in the DVT group than in the control group (p < 0.05). LDL-C levels were significantly higher (p < 0.001) in DVT patients than in the control subjects (Table 1 ). There were no significant differences between the groups in age, HDL-C, and TG level (Table 1 ). Ten percent of the patients with DVT were diabetic, and 20% had hypertension and obesity.
In VT patients, tHcy levels were inversely correlated to TG (r = -0.358; p = 0.023) and TC (r = -0.454; p = 0.003). No relationship was found between homocysteine level and other factors (age, HDL-C, LDL-C, and creatinine level) ( Table 2) .
The logistic regression analysis showed that the variables independently associated with tHcy were TC [OR 2.1, 95% confidence interval (CI) 1.7-2.6], LDL-C (OR 2.0, 95% CI 1.6-2.5), creatinine (OR 2.2, 95% CI 1.7-2.6), and smoking (OR 2.1, 95% CI 1.7-2.5) ( Table 3) .
To assess the independent contribution of the variables to Hcy levels in VT patients, multiple regression analysis was performed, which included all variables significantly associated with Hcy by univariate analyses. Effectively, TG (β = -0.03; p = 0.023) and TC (β = -0.05; p = 0.003) were the only independent predictors of DVT in our study group (Table 4) .
Examination of the interaction effects revealed the following significant interactions in a multivariate regression model: for tHcy × TC × TG (r = 0.514, p = 0.003) and for tHcy × TG (r = 0.358, p = 0.023).
Discussion
To our knowledge, this is the first study focusing on the association and interaction of the tHcy implicated in the Algerian population with DVT. There have been a number of studies concerning the relation between Hcy and DVT. A study by Den Heijer et al. [10] showed a prevalence of HHcy of 10%. Simioni et al. [16] in their case control study showed that the prevalence of HHcy was 25%. In our study, the prevalence of HHcy in patients with DVT was found to be 27.5% and in the control subjects was 3.4%. Our study shows that the association between Hcy and DVT was not confirmed in this study.
It is possible that this association diminishes in populations with high prevalence of HHcy [17] [18] [19] . In 1991, Brattstrom et al. [20] published a study in which average Hcy concentrations did not differ between patients with VTE and controls; this finding was confirmed by our group. Bienvenu et al. [21] found a distinct difference in Hcy concentrations between patients with either arterial or venous thrombosis and healthy controls. An increase in the risk was already seen at Hcy concentrations of 14.0 μmol/L [11] . As yet, there is no clear evidence how HHcy could lead to VT.
Falcon et al. [22] reported that HHcy was a risk factor for juvenile thrombosis. Consequently, Den Heijer et al. [10] reported that HHcy is a risk factor for recurrent VT in patients between 20 and 70 years of age, as compared with controls from the general population. In our study, there was no statistical significance in the prevalence of HHcy between the different age and sex groups. This is not consistent with finding in other studies; thus the prevalence was higher in males as than in females [10, 23, 24] . This residual sex difference may be explained by the tHcy formation in connection with the creatine/creatinine synthesis, which is proportional to muscle mass [25] . This indicates that the tHcy levels in the older age group may have been influenced by factors related to homocysteine metabolism other than vitamin levels, such as the decreased activity of several related enzymes [26] , physiologic decline in renal function [27] , and hormonal changes [28] in the elderly.
Additional risk factors such as smoking, arterial hypertension, diabetes, and hyperlipidaemia may additively or synergistically increase the overall risk [29] . Although cigarette smoking is a known risk factor for HHcy [30] , our study shows a statistically significant association between them in multivariate regression analysis. However, the relationships between cigarette smoking and tHcy concentrations are controversial. Higher levels of Hcy in smokers than in non-smokers have been demonstrated in some [31] [32] [33] , but not all [34] , smaller studies. tHcy levels correlated with other cardiovascular risk factor such as triglycerides [35] . The present study showed that the plasma level of tHcy was associated with the TC and TG levels, and this was true not only in the univariate analysis but also in the logistic regression analysis. The odds ratio between the plasma levels of Hcy and TC, LDL, creatinine, and smoking, respectively, was significant in our patients with DVT. The tHcy level was independently associated with the TG and TC levels in our patients, according to the multiple logistic regression analysis. Consequently, tHcy, TG, and TC levels may be a useful biomarker for the increased risk of DVT. However, this relationship was partly attenuated in a multiple regression model including age, HDL-C, and creatinine level.
The plasma Hcy differences observed were independent of plasma creatinine concentration. The homocysteine/creatinine ratio could be a tool to study Hcy homeostasis in some pathological conditions such as neural tube defects and vascular diseases [36] . A positive correlation between serum creatinine level, glomerular filtration rate, and Hcy level was seen [37] . Thus, both hyperhomocysteinaemia and renal injury are associated with each other as pathogenic processes, creating a vicious cycle that results in further deterioration of renal function [38] . However, in Dogra et al. [39] , their findings do not provide a supportive evidence for altered Hcy metabolism in nephrotic syndrome and Hcy does not appear to contribute to the increased risk of CVD seen in nephrosis.
Our data are compatible with the hypothesis that TG and TC levels may influence plasma Hcy levels and, hence, vascular disease risk; most findings did not reach statistical significance, possibly due to the relatively small numbers of subjects. A strong effect modification of the tHcy-CVD association by conventional risk factors may also explain the observation that tHcy is not related to coronary heart disease in patients without conventional risk factors such as hypertension, diabetes, and hyperlipidaemia [40] .
HHcy remained a risk factor for DVT after we excluded subjects with other well-established risk factors; that is, the association with thrombosis was not explained by the presence of other hereditary risk factors for thrombosis. Consequently, HHcy may interact with the genetic predisposition to thrombosis, as was shown for the factor V Lieden (FVL) mutation [41] . According to our previous research [42] , methylenetetrahydrofolate reductase (MTHFR) 677 C-T prevalence is quite high and the coexistence of the MTHFR 677 C-T enzyme defect with other hereditary causes of thrombosis, such as FVL and prothrombin (PT) 20210 G-A mutations, is rare in healthy populations of the Sétif region of Algeria.
The frequency of the 677 C-T polymorphisms in homozygosis, but not in heterozygosis, for cardiovascular diseases in our patients was not significantly different as compared to the control group [43] , suggesting that this polymorphism does not contribute to the development of DVT in our population. It is generally accepted that the MTHFR 677 C-T polymorphism alone is not a risk factor for thrombosis [44] , and according to some, but not all, studies, this confers a risk for arterial and venous thrombosis [45, 46] . In the homozygous state, however, this variant can be considered as a risk factor when associated with other thrombophilic conditions [47] . Factors such as hereditary predisposition, ethnic origin, gender, age, and diet affect Hcy level, but the mechanisms by which Hcy causes thrombosis are largely unknown [8] .
In conclusion, in the present study, which is the first conducted in Algeria, we do not postulate that HHcy might be associated with a higher risk of DVT among our patients relatively compared to several populations worldwide [2, 23, 48] . Although the association between HHcy and DVT was not confirmed in this study, it is possible that this association diminishes in populations with a high prevalence of HHcy. Unlike other risk factors, HHcy is readily reversible in most individuals with supplementation of folic acid and other vitamins.
It was suggested that nutritional folate deficiency was related to HHcy through the thrombotic side effects of vascular disease [49] . A decrease in serum Hcy of 3 μmol/L (achievable by a daily intake of about 0.8 mg of folic acid) should reduce the risk of DVT by 25% [50] . The folic acid supplement could be taken in tablet form by highrisk patients and possibly supplied to the general public through food fortification or a combination of both. Our results will serve as a baseline to investigate the possible causes of DVT in our population.
